Agios to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025
Agios Pharmaceuticals (Nasdaq: AGIO), a company specializing in cellular metabolism and PK activation therapies for rare diseases, has announced its upcoming participation at the 43rd Annual J.P. Morgan Healthcare Conference. The presentation is scheduled for Wednesday, January 15, 2025, at 7:30 a.m. PT / 10:30 a.m. ET.
The company will provide a live webcast of the presentation, which will be available through the Investors section of Agios's website under the Events & Presentations tab. Interested parties can access the replay of the webcast on the company's website, where it will remain available for a minimum of two weeks following the presentation.
Agios Pharmaceuticals (Nasdaq: AGIO), un'azienda specializzata nelle terapie per il metabolismo cellulare e nell'attivazione delle PK per malattie rare, ha annunciato la sua prossima partecipazione alla 43ª Conferenza Annuale J.P. Morgan Healthcare. La presentazione è programmata per mercoledì 15 gennaio 2025, alle 7:30 ora PT / 10:30 ora ET.
L'azienda offrirà un webcast dal vivo della presentazione, che sarà disponibile nella sezione Investitori del sito web di Agios, sotto la scheda Eventi e Presentazioni. Le parti interessate potranno accedere alla registrazione del webcast sul sito dell'azienda, dove rimarrà disponibile per un periodo minimo di due settimane dopo la presentazione.
Agios Pharmaceuticals (Nasdaq: AGIO), una compañía especializada en metabolismo celular y terapias de activación de PK para enfermedades raras, ha anunciado su próxima participación en la 43ª Conferencia Anual de Atención Médica de J.P. Morgan. La presentación está programada para miércoles 15 de enero de 2025, a las 7:30 a.m. PT / 10:30 a.m. ET.
La compañía proporcionará una transmisión en vivo de la presentación, que estará disponible a través de la sección de Inversores en el sitio web de Agios, en la pestaña de Eventos y Presentaciones. Las partes interesadas podrán acceder a la grabación de la transmisión en el sitio web de la compañía, donde permanecerá disponible durante un mínimo de dos semanas después de la presentación.
Agios Pharmaceuticals (Nasdaq: AGIO)는 희귀 질환을 위한 세포 대사 및 PK 활성화 치료를 전문으로 하는 회사로, 제43회 JP모건 헬스케어 콘퍼런스에 참가할 예정이라고 발표했습니다. 발표는 2025년 1월 15일 수요일 오전 7시 30분 PT / 오전 10시 30분 ET에 예정되어 있습니다.
회사는 발표의 라이브 웹캐스트를 제공하며, 이는 Agios 웹사이트의 투자자 섹션에서 이벤트 및 발표 탭 아래에서 이용 가능할 것입니다. 관심 있는 분들은 발표 후 최소 2주 동안 회사의 웹사이트에서 웹캐스트 재생을 이용할 수 있습니다.
Agios Pharmaceuticals (Nasdaq: AGIO), une entreprise spécialisée dans le métabolisme cellulaire et les thérapies d'activation de PK pour les maladies rares, a annoncé sa prochaine participation à la 43e Conférence Annuelle J.P. Morgan Healthcare. La présentation est prévue pour mercredi 15 janvier 2025, à 7h30 PT / 10h30 ET.
L'entreprise proposera une diffusion en direct de la présentation, qui sera disponible dans la section Investisseurs du site web d'Agios, sous l'onglet Événements et Présentations. Les parties intéressées pourront accéder à la rediffusion de la diffusion sur le site de l'entreprise, où elle restera disponible pendant au moins deux semaines après la présentation.
Agios Pharmaceuticals (Nasdaq: AGIO), ein Unternehmen, das sich auf Zellstoffwechsel und PK-Aktivierungstherapien für seltene Krankheiten spezialisiert hat, hat seine bevorstehende Teilnahme an der 43. Jahreskonferenz von J.P. Morgan Healthcare angekündigt. Die Präsentation ist für Mittwoch, den 15. Januar 2025, um 7:30 Uhr PT / 10:30 Uhr ET geplant.
Das Unternehmen wird einen Live-Webcast der Präsentation anbieten, der über den Bereich Investoren auf der Website von Agios unter dem Tab Veranstaltungen & Präsentationen verfügbar sein wird. Interessierte können die Wiederholung des Webcasts auf der Website des Unternehmens abrufen, wo er mindestens zwei Wochen nach der Präsentation verfügbar bleibt.
- None.
- None.
CAMBRIDGE, Mass., Jan. 03, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced that its management team is scheduled to present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 7:30 a.m. PT / 10:30 a.m. ET.
The live webcast will be accessible on the Investors section of the company's website (www.agios.com) under the “Events & Presentations” tab. A replay of the webcast will be archived on the company’s website for at least two weeks following the presentation.
About Agios
Agios is the pioneering leader in PK activation and is dedicated to developing and delivering transformative therapies for patients living with rare diseases. In the U.S., Agios markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for this rare, lifelong, debilitating hemolytic anemia. Building on the company's deep scientific expertise in classical hematology and leadership in the field of cellular metabolism and rare hematologic diseases, Agios is advancing a robust clinical pipeline of investigational medicines with programs in alpha- and beta-thalassemia, sickle cell disease, pediatric PK deficiency, myelodysplastic syndromes (MDS)-associated anemia and phenylketonuria (PKU). In addition to its clinical pipeline, Agios is advancing a preclinical TMPRSS6 siRNA as a potential treatment for polycythemia vera. For more information, please visit the company’s website at www.agios.com.
Contacts:
Investor Contact
Chris Taylor, VP, Investor Relations and Corporate Communications
Agios Pharmaceuticals
IR@agios.com
Media Contact
Eamonn Nolan, Senior Director, Corporate Communications
Agios Pharmaceuticals
Media@agios.com
FAQ
When is Agios Pharmaceuticals (AGIO) presenting at the 2025 J.P. Morgan Healthcare Conference?
How can investors watch Agios's (AGIO) J.P. Morgan Healthcare Conference presentation?
How long will the replay of AGIO's 2025 J.P. Morgan presentation be available?
What is Agios Pharmaceuticals' (AGIO) primary business focus?
